Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 5697

1.

A Novel SYNJ1 Mutation in a Tunisian Family with Juvenile Parkinson's Disease Associated with Epilepsy.

Ben Romdhan S, Sakka S, Farhat N, Triki S, Dammak M, Mhiri C.

J Mol Neurosci. 2018 Sep 5. doi: 10.1007/s12031-018-1167-2. [Epub ahead of print]

PMID:
30187305
2.

Non-cell-autonomous actions of α-synuclein: Implications in glial synucleinopathies.

Lim S, Kim HJ, Kim DK, Lee SJ.

Prog Neurobiol. 2018 Oct;169:158-171. doi: 10.1016/j.pneurobio.2018.06.010. Epub 2018 Jul 3. Review.

PMID:
30173732
3.

Mitochondrial Dysfunction and Mitophagy Defect Triggered by Heterozygous GBA Mutations.

Li H, Ham A, Ma TC, Kuo SH, Kanter E, Kim D, Ko HS, Quan Y, Sardi SP, Li A, Arancio O, Kang UJ, Sulzer D, Tang G.

Autophagy. 2018 Aug 30. doi: 10.1080/15548627.2018.1509818. [Epub ahead of print]

PMID:
30160596
4.

A comprehensive analysis of SNCA-related genetic risk in sporadic parkinson disease.

Pihlstrøm L, Blauwendraat C, Cappelletti C, Berge-Seidl V, Langmyhr M, Henriksen SP, van de Berg WDJ, Gibbs JR, Cookson MR; International Parkinson Disease Genomics Consortium; North American Brain Expression Consortium, Singleton AB, Nalls MA, Toft M.

Ann Neurol. 2018 Jul;84(1):117-129. doi: 10.1002/ana.25274. Epub 2018 Aug 26.

PMID:
30146727
5.

Exploring genetic modifiers of Gaucher disease: The next horizon.

Davidson BA, Hassan S, Garcia EJ, Tayebi N, Sidransky E.

Hum Mutat. 2018 Aug 10. doi: 10.1002/humu.23611. [Epub ahead of print] Review.

PMID:
30098107
6.

The G2019S mutation in LRRK2 imparts resiliency to kinase inhibition.

Kelly K, Wang S, Boddu R, Liu Z, Moukha-Chafiq O, Augelli-Szafran C, West AB.

Exp Neurol. 2018 Nov;309:1-13. doi: 10.1016/j.expneurol.2018.07.012. Epub 2018 Jul 24.

7.

Frequency of Loss of Function Variants in LRRK2 in Parkinson Disease.

Blauwendraat C, Reed X, Kia DA, Gan-Or Z, Lesage S, Pihlstrøm L, Guerreiro R, Gibbs JR, Sabir M, Ahmed S, Ding J, Alcalay RN, Hassin-Baer S, Pittman AM, Brooks J, Edsall C, Hernandez DG, Chung SJ, Goldwurm S, Toft M, Schulte C, Bras J, Wood NW, Brice A, Morris HR, Scholz SW, Nalls MA, Singleton AB, Cookson MR; COURAGE-PD (Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson’s Disease) Consortium, the French Parkinson’s Disease Consortium, and the International Parkinson’s Disease Genomics Consortium (IPDGC).

JAMA Neurol. 2018 Jul 23. doi: 10.1001/jamaneurol.2018.1885. [Epub ahead of print]

PMID:
30039155
8.

Sequencing of the GBA coactivator, Saposin C, in Parkinson disease.

Ouled Amar Bencheikh B, Leveille E, Ruskey JA, Spiegelman D, Liong C, Fon EA, Rouleau GA, Dauvilliers Y, Dupre N, Alcalay RN, Gan-Or Z.

Neurobiol Aging. 2018 Jul 2. pii: S0197-4580(18)30239-2. doi: 10.1016/j.neurobiolaging.2018.06.034. [Epub ahead of print]

PMID:
30037697
9.

Computational modelling approaches as a potential platform to understand the molecular genetics association between Parkinson's and Gaucher diseases.

Thirumal Kumar D, Eldous HG, Mahgoub ZA, George Priya Doss C, Zayed H.

Metab Brain Dis. 2018 Jul 6. doi: 10.1007/s11011-018-0286-3. [Epub ahead of print]

PMID:
29978341
10.

Activity of translation regulator eukaryotic elongation factor-2 kinase is increased in Parkinson disease brain and its inhibition reduces alpha synuclein toxicity.

Jan A, Jansonius B, Delaidelli A, Bhanshali F, An YA, Ferreira N, Smits LM, Negri GL, Schwamborn JC, Jensen PH, Mackenzie IR, Taubert S, Sorensen PH.

Acta Neuropathol Commun. 2018 Jul 2;6(1):54. doi: 10.1186/s40478-018-0554-9.

11.

Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study.

De Pablo-Fernandez E, Goldacre R, Pakpoor J, Noyce AJ, Warner TT.

Neurology. 2018 Jul 10;91(2):e139-e142. doi: 10.1212/WNL.0000000000005771. Epub 2018 Jun 13.

PMID:
29898968
12.

Import and Export of Misfolded α-Synuclein.

Rodriguez L, Marano MM, Tandon A.

Front Neurosci. 2018 May 23;12:344. doi: 10.3389/fnins.2018.00344. eCollection 2018. Review.

13.

Regional expression of genes mediating trans-synaptic alpha-synuclein transfer predicts regional atrophy in Parkinson disease.

Freeze B, Acosta D, Pandya S, Zhao Y, Raj A.

Neuroimage Clin. 2018 Jan 31;18:456-466. doi: 10.1016/j.nicl.2018.01.009. eCollection 2018.

14.

A Proposed Mechanism for Neurodegeneration in Movement Disorders Characterized by Metal Dyshomeostasis and Oxidative Stress.

Trist BG, Hare DJ, Double KL.

Cell Chem Biol. 2018 Jul 19;25(7):807-816. doi: 10.1016/j.chembiol.2018.05.004. Epub 2018 May 31. Review.

PMID:
29861271
15.

RIT2: responsible and susceptible gene for neurological and psychiatric disorders.

Daneshmandpour Y, Darvish H, Emamalizadeh B.

Mol Genet Genomics. 2018 Aug;293(4):785-792. doi: 10.1007/s00438-018-1451-4. Epub 2018 Jun 2. Review.

PMID:
29860660
16.

Taq1A polymorphism and medication effects on inhibitory action control in Parkinson disease.

McDonell KE, van Wouwe NC, Harrison MB, Wylie SA, Claassen DO.

Brain Behav. 2018 Jul;8(7):e01008. doi: 10.1002/brb3.1008. Epub 2018 Jun 1.

17.

The REM sleep circuit and how its impairment leads to REM sleep behavior disorder.

Iranzo A.

Cell Tissue Res. 2018 Jul;373(1):245-266. doi: 10.1007/s00441-018-2852-8. Epub 2018 May 30. Review.

PMID:
29846796
18.

PINK1 Type of Young-Onset Parkinson Disease.

Schneider SA, Klein C.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018.
2010 Mar 16 [updated 2018 May 24].

19.

Non-motor Parkinson disease: new concepts and personalised management.

Titova N, Chaudhuri KR.

Med J Aust. 2018 May 21;208(9):404-409.

PMID:
29764353
20.

Identifying genes in Parkinson disease: state of the art.

Chew EG, Foo JN, Tan EK.

Med J Aust. 2018 May 21;208(9):381-382. No abstract available.

PMID:
29764346

Supplemental Content

Loading ...
Support Center